Trinity Biotech Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

John Gillard

Geschäftsführender

US$710.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts66.6%
Amtszeit als Geschäftsführer3.7yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements6.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder1.8yrs

Jüngste Management Updates

Recent updates

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01
At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

Jun 14
Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 23
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

Feb 25
Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

Feb 02
Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

A Treatise On Trinity Biotech

Jan 13

Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?

Jan 05
Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?

What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?

Dec 10
What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?

Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt

Nov 19
Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt

Trinity Biotech EPS beats by $0.22, beats on revenue

Nov 17

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von John Gillard im Vergleich zu den Einnahmen von Trinity Biotech verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$710kUS$473k

-US$37m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023n/an/a

-US$34m

Dec 31 2022US$863kUS$452k

-US$44m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$593kUS$346k

-US$2m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$2m

Dec 31 2020US$312kUS$52k

-US$6m

Vergütung im Vergleich zum Markt: JohnDie Gesamtvergütung ($USD710.00K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD678.50K).

Entschädigung vs. Einkommen: JohnDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

John Gillard (43 yo)

3.7yrs

Amtszeit

US$710,000

Vergütung

Mr. John Gillard is President & CEO of Trinity Biotech plc since December 17, 2023 and served as Chief Financial Officer since November 17, 2020 until December 17, 2023. He serves as Executive Director at...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
John Gillard
President3.7yrsUS$710.00kkeine Daten
Ronan O'Caoimh
Founderno dataUS$80.00k5.14%
$ 1.0m
James Walsh
Executive Director of Business Development & Executive Directorno dataUS$50.00k0.74%
$ 148.4k
Des Fitzgerald
Interim Chief Financial Officerless than a yearkeine Daten0%
$ 0
Jacqueline O'Neill
Director of Operationsno datakeine Datenkeine Daten
Simon Dunne
Chief Accounting Officer16.7yrskeine Daten0%
$ 0
Gary Keating
Chief Technology Officerno datakeine Datenkeine Daten
Eibhlin Kelly
Chief Information Officer8.8yrskeine Datenkeine Daten
Colm Molloy
Group Director of Human Resources & Cultureno datakeine Datenkeine Daten

6.3yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: TRIBDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.2 ).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
John Gillard
President3.7yrsUS$710.00kkeine Daten
Ronan O'Caoimh
Founder1.8yrsUS$80.00k5.14%
$ 1.0m
James Walsh
Executive Director of Business Development & Executive Director17.5yrsUS$50.00k0.74%
$ 148.4k
Andrew Omidvar
Independent Directorless than a yearUS$10.00k0%
$ 0
Thomas Lindsay
Independent Non-Executive Director1.8yrsUS$63.00k0%
$ 0

1.8yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: TRIBDie Vorstandsmitglieder gelten nicht als erfahren ( 1.7 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.